← All trials
NCT04879368
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Jun 1, 2025
- Completion date
- Jun 1, 2026
- First posted
- May 10, 2021
- Last posted
- Aug 30, 2021
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Australasian Gastro-Intestinal Trials GroupLead sponsor
- Academic and Community Cancer Research UnitedCollaborator
- Australasian Gastro-Intestinal Trials GroupStudy chair
- BayerCollaborator
- IKF Klinische Krebsforschung GmbH am Krankenhaus NordwestCollaborator
- National Cancer Center, JapanCollaborator
- Syneos HealthCollaborator
- Taiwan Cooperative Oncology GroupCollaborator
- University of SydneyCollaborator
- Australasian Gastro-Intestinal Trials GroupOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.